INTRODUCTION: Elevated levels of chemokines have been reported in plasma and brain tissue of individuals with Autism Spectrum Disorders (ASD). The aim of this study was to examine chemokine levels in amniotic fluid (AF) samples of individuals diagnosed with ASD and their controls. MATERIAL AND METHODS: A Danish Historic Birth Cohort (HBC) kept at Statens Serum Institute, Copenhagen was utilized. Using data from Danish nation-wide health registers, a case-control study design of 414 cases and 820 controls was adopted. Levels of MCP-1, MIP-1α and RANTES were analyzed using Luminex xMAP technology. Case-control differences were assessed as dichotomized at below the 10th percentile or above the 90th percentile cut-off points derived from the control biomarker distributions (logistic regression) or continuous measures (tobit regression). RESULTS AND CONCLUSION: AF volume for 331 cases and 698 controls was sufficient for Luminex analysis. Including all individuals in the cohort yielded no significant differences in chemokine levels in cases versus controls. Logistic regression analyses, performed on individuals diagnosed using ICD-10 only, showed increased risk for ASD with elevated MCP-1 (elevated 90th percentile adjusted OR: 2.32 [95% CI: 1.17-4.61]) compared to controls. An increased risk for infantile autism with elevated MCP-1 was also found (adjusted OR: 2.28 [95% CI: 1.16-4.48]). Elevated levels of MCP-1 may decipher an etiologic immunologic dysfunction or play rather an indirect role in the pathophysiology of ASD. Further studies to confirm its role and to identify the potential pathways through which MCP-1 may contribute to the development of ASD are necessary.
INTRODUCTION: Elevated levels of chemokines have been reported in plasma and brain tissue of individuals with Autism Spectrum Disorders (ASD). The aim of this study was to examine chemokine levels in amniotic fluid (AF) samples of individuals diagnosed with ASD and their controls. MATERIAL AND METHODS: A Danish Historic Birth Cohort (HBC) kept at Statens Serum Institute, Copenhagen was utilized. Using data from Danish nation-wide health registers, a case-control study design of 414 cases and 820 controls was adopted. Levels of MCP-1, MIP-1α and RANTES were analyzed using Luminex xMAP technology. Case-control differences were assessed as dichotomized at below the 10th percentile or above the 90th percentile cut-off points derived from the control biomarker distributions (logistic regression) or continuous measures (tobit regression). RESULTS AND CONCLUSION:AF volume for 331 cases and 698 controls was sufficient for Luminex analysis. Including all individuals in the cohort yielded no significant differences in chemokine levels in cases versus controls. Logistic regression analyses, performed on individuals diagnosed using ICD-10 only, showed increased risk for ASD with elevated MCP-1 (elevated 90th percentile adjusted OR: 2.32 [95% CI: 1.17-4.61]) compared to controls. An increased risk for infantile autism with elevated MCP-1 was also found (adjusted OR: 2.28 [95% CI: 1.16-4.48]). Elevated levels of MCP-1 may decipher an etiologic immunologic dysfunction or play rather an indirect role in the pathophysiology of ASD. Further studies to confirm its role and to identify the potential pathways through which MCP-1 may contribute to the development of ASD are necessary.
Authors: Natalia V Malkova; Collin Z Yu; Elaine Y Hsiao; Marlyn J Moore; Paul H Patterson Journal: Brain Behav Immun Date: 2012-01-30 Impact factor: 7.217
Authors: Sheikh F Ahmad; Mushtaq A Ansari; Ahmed Nadeem; Saleh A Bakheet; Raish Mohammad; Sabry M Attia Journal: Mol Neurobiol Date: 2017-04-18 Impact factor: 5.590
Authors: Jessica L Irwin; Alison J Yeates; Maria S Mulhern; Emeir M McSorley; J J Strain; Gene E Watson; Katherine Grzesik; Sally W Thurston; Tanzy M Love; Tristram H Smith; Daniel W Mruzek; Conrad F Shamlaye; Catriona Monthy; Gary J Myers; Philip W Davidson; Edwin van Wijngaarden Journal: Mol Neurobiol Date: 2018-11-14 Impact factor: 5.590
Authors: Elaine Y Hsiao; Sara W McBride; Janet Chow; Sarkis K Mazmanian; Paul H Patterson Journal: Proc Natl Acad Sci U S A Date: 2012-07-16 Impact factor: 11.205
Authors: Charity E Onore; Jared J Schwartzer; Milo Careaga; Robert F Berman; Paul Ashwood Journal: Brain Behav Immun Date: 2014-02-22 Impact factor: 7.217
Authors: Jessica L Irwin; Emeir M McSorley; Alison J Yeates; Maria S Mulhern; J J Strain; Gene E Watson; Katherine Grzesik; Sally W Thurston; Tanzy M Love; Tristram H Smith; Karin Broberg; Conrad F Shamlaye; Gary J Myers; Philip W Davidson; Edwin van Wijngaarden Journal: J Neuroimmunol Date: 2019-08-14 Impact factor: 3.478
Authors: Irene Knuesel; Laurie Chicha; Markus Britschgi; Scott A Schobel; Michael Bodmer; Jessica A Hellings; Stephen Toovey; Eric P Prinssen Journal: Nat Rev Neurol Date: 2014-10-14 Impact factor: 42.937